End-of-day quote
Pakistan S.E.
18:00:00 2024-06-30 EDT
|
5-day change
|
1st Jan Change
|
92.86
PKR
|
+0.53%
|
|
+5.00%
|
+32.07%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
24,480
|
27,818
|
31,886
|
27,157
|
18,197
|
19,687
|
Enterprise Value (EV)
1 |
26,283
|
28,909
|
32,557
|
29,556
|
21,160
|
31,282
|
P/E ratio
|
20.3
x
|
19.2
x
|
20.1
x
|
15.5
x
|
11.6
x
|
12.6
x
|
Yield
|
1.43%
|
3.27%
|
1.76%
|
2.58%
|
3.08%
|
3.56%
|
Capitalization / Revenue
|
4.55
x
|
4.45
x
|
4.59
x
|
2.91
x
|
1.26
x
|
1.05
x
|
EV / Revenue
|
4.88
x
|
4.62
x
|
4.69
x
|
3.17
x
|
1.46
x
|
1.67
x
|
EV / EBITDA
|
15
x
|
13.2
x
|
14.7
x
|
11.2
x
|
6.6
x
|
6.82
x
|
EV / FCF
|
74
x
|
38.7
x
|
37.3
x
|
-13
x
|
-531
x
|
-3.79
x
|
FCF Yield
|
1.35%
|
2.58%
|
2.68%
|
-7.69%
|
-0.19%
|
-26.4%
|
Price to Book
|
3.84
x
|
3.73
x
|
3.88
x
|
2.81
x
|
1.73
x
|
1.72
x
|
Nbr of stocks (in thousands)
|
280,000
|
280,000
|
280,000
|
280,000
|
280,000
|
280,000
|
Reference price
2 |
87.43
|
99.35
|
113.9
|
96.99
|
64.99
|
70.31
|
Announcement Date
|
3/26/19
|
4/14/20
|
4/5/21
|
3/24/22
|
3/22/23
|
2/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
5,382
|
6,253
|
6,946
|
9,317
|
14,459
|
18,743
|
EBITDA
1 |
1,757
|
2,192
|
2,217
|
2,638
|
3,208
|
4,588
|
EBIT
1 |
1,653
|
2,066
|
2,080
|
2,470
|
2,969
|
4,285
|
Operating Margin
|
30.72%
|
33.04%
|
29.94%
|
26.51%
|
20.54%
|
22.86%
|
Earnings before Tax (EBT)
1 |
1,426
|
1,825
|
1,927
|
2,308
|
2,441
|
2,635
|
Net income
1 |
1,207
|
1,446
|
1,587
|
1,747
|
1,570
|
1,565
|
Net margin
|
22.42%
|
23.13%
|
22.85%
|
18.75%
|
10.86%
|
8.35%
|
EPS
2 |
4.310
|
5.166
|
5.669
|
6.240
|
5.607
|
5.590
|
Free Cash Flow
1 |
355
|
747.2
|
873.8
|
-2,273
|
-39.85
|
-8,245
|
FCF margin
|
6.6%
|
11.95%
|
12.58%
|
-24.39%
|
-0.28%
|
-43.99%
|
FCF Conversion (EBITDA)
|
20.21%
|
34.09%
|
39.41%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
29.42%
|
51.66%
|
55.05%
|
-
|
-
|
-
|
Dividend per Share
2 |
1.250
|
3.250
|
2.000
|
2.500
|
2.000
|
2.500
|
Announcement Date
|
3/26/19
|
4/14/20
|
4/5/21
|
3/24/22
|
3/22/23
|
2/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
1,803
|
1,091
|
671
|
2,398
|
2,962
|
11,595
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.026
x
|
0.4977
x
|
0.3027
x
|
0.9091
x
|
0.9234
x
|
2.527
x
|
Free Cash Flow
1 |
355
|
747
|
874
|
-2,273
|
-39.9
|
-8,245
|
ROE (net income / shareholders' equity)
|
20.3%
|
20.9%
|
20.3%
|
20.1%
|
16%
|
15.5%
|
ROA (Net income/ Total Assets)
|
11.8%
|
13.9%
|
13.1%
|
12.3%
|
11.8%
|
12%
|
Assets
1 |
10,211
|
10,398
|
12,087
|
14,181
|
13,288
|
13,006
|
Book Value Per Share
2 |
22.70
|
26.70
|
29.30
|
34.60
|
37.70
|
40.90
|
Cash Flow per Share
2 |
0.0900
|
0.4200
|
1.320
|
1.630
|
0.7700
|
0.7200
|
Capex
1 |
337
|
433
|
364
|
481
|
933
|
734
|
Capex / Sales
|
6.26%
|
6.93%
|
5.25%
|
5.16%
|
6.45%
|
3.92%
|
Announcement Date
|
3/26/19
|
4/14/20
|
4/5/21
|
3/24/22
|
3/22/23
|
2/29/24
|
|
1st Jan change
|
Capi.
|
---|
| +32.07% | 92.93M | | +56.86% | 815B | | +43.90% | 641B | | -6.57% | 352B | | +17.32% | 314B | | +9.94% | 303B | | +16.08% | 242B | | +2.29% | 224B | | +13.96% | 218B | | +7.98% | 168B |
Other Pharmaceuticals
|